ES2093776T3 - Metodo para producir cetolactonas alfa,beta-insaturadas. - Google Patents

Metodo para producir cetolactonas alfa,beta-insaturadas.

Info

Publication number
ES2093776T3
ES2093776T3 ES92302992T ES92302992T ES2093776T3 ES 2093776 T3 ES2093776 T3 ES 2093776T3 ES 92302992 T ES92302992 T ES 92302992T ES 92302992 T ES92302992 T ES 92302992T ES 2093776 T3 ES2093776 T3 ES 2093776T3
Authority
ES
Spain
Prior art keywords
beta
producing alpha
ketolactones
unsaturated
unsaturated ketolactones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92302992T
Other languages
English (en)
Spanish (es)
Inventor
Ryuji Ueno
Tomio Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R Tech Ueno Ltd
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Application granted granted Critical
Publication of ES2093776T3 publication Critical patent/ES2093776T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Furan Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES92302992T 1991-04-04 1992-04-03 Metodo para producir cetolactonas alfa,beta-insaturadas. Expired - Lifetime ES2093776T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7148391 1991-04-04

Publications (1)

Publication Number Publication Date
ES2093776T3 true ES2093776T3 (es) 1997-01-01

Family

ID=13461939

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92302992T Expired - Lifetime ES2093776T3 (es) 1991-04-04 1992-04-03 Metodo para producir cetolactonas alfa,beta-insaturadas.

Country Status (11)

Country Link
US (1) US5229529A (enExample)
EP (1) EP0507625B1 (enExample)
JP (1) JPH089608B2 (enExample)
KR (1) KR970003125B1 (enExample)
AT (1) ATE141921T1 (enExample)
CA (1) CA2064481C (enExample)
DE (1) DE69213067T2 (enExample)
DK (1) DK0507625T3 (enExample)
ES (1) ES2093776T3 (enExample)
GR (1) GR3020903T3 (enExample)
TW (1) TW197439B (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT643051E (pt) * 1992-09-30 2000-06-30 R Tech Ueno Ltd Processo de producao de cetonas alfa,beta-insaturadas
CA2178541C (en) 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
WO2002085337A1 (en) * 2001-04-20 2002-10-31 The University Of British Columbia Micellar drug delivery systems for hydrophobic drugs
JP4358940B2 (ja) * 1999-08-26 2009-11-04 丸善石油化学株式会社 シクロヘキサンラクトン構造を有する重合性化合物及び重合体
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
EP1418945A2 (en) * 2001-03-13 2004-05-19 Angiotech Pharmaceuticals, Inc. Micellar drug delivery vehicles and uses thereof
US20030216758A1 (en) * 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
DE10220729A1 (de) * 2002-05-08 2003-11-20 Martin Foerster Verfahren zum Bestimmen einer von Tieren gesoffenen Menge an flüssigen Nahrungsmitteln
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
JP2007525188A (ja) 2003-05-16 2007-09-06 インターミューン インコーポレイテッド 合成ケモカイン受容体リガンドおよびその使用方法
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
CA2576030A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
WO2006089218A2 (en) * 2005-02-17 2006-08-24 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating angiogenesis
US20070073385A1 (en) * 2005-09-20 2007-03-29 Cook Incorporated Eluting, implantable medical device
CN103804338A (zh) * 2006-02-07 2014-05-21 株式会社·R-技术上野 用于制备前列腺素衍生物的方法
AU2007228984B2 (en) 2006-03-22 2012-05-03 Syncore Biotechnology Co., Ltd Treatment of triple receptor negative breast cancer
WO2008005284A2 (en) 2006-06-30 2008-01-10 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20080241215A1 (en) * 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
US8409601B2 (en) * 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8273404B2 (en) * 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
EP2296645B1 (en) 2008-05-22 2014-11-19 Galera Therapeutics, LLC Combination antitumor therapy
WO2010005850A1 (en) 2008-07-08 2010-01-14 The J. David Gladstone Institutes Methods and compositions for modulating angiogenesis
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
EP2337563B1 (en) 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
EP2429982A4 (en) 2009-01-22 2012-09-12 Apotex Pharmachem Inc METHOD FOR THE PRODUCTION OF LUBIPROSTON AND INTERMEDIATE PRODUCTS THEREOF
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
JP6578206B2 (ja) 2012-07-19 2019-09-18 レッドウッド バイオサイエンス， インコーポレイテッド Ｃｄ２２に特異的な抗体およびその使用方法
WO2014074218A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
SI3300745T1 (sl) 2013-02-15 2020-01-31 The Regents Of The University Of California Himerni antigenski receptor in postopki njihove uporabe
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CN105744935B (zh) 2013-11-27 2022-09-30 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
WO2015127137A1 (en) 2014-02-19 2015-08-27 Aldea Pharmaceuticals, Inc. Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer
CA2995029C (en) 2015-09-25 2022-10-25 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
WO2017083637A1 (en) 2015-11-12 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
EP3463308B2 (en) 2016-06-01 2026-01-07 Servier IP UK Limited Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
TWI852903B (zh) 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
KR102905343B1 (ko) 2017-01-18 2025-12-29 바이오아트라, 인코퍼레이티드 Axl 또는 ror2에 대한 키메라 항원 수용체 및 이의 사용 방법
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
CN118652192A (zh) 2017-05-24 2024-09-17 德克萨斯州大学系统董事会 用于抗体药物缀合物的接头
IL276407B2 (en) 2018-01-31 2025-01-01 Galera Labs Llc Combination cancer therapy with a pentase macrocyclic ring complex and a platinum-based anticancer agent
CA3095757A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
EP3773632A4 (en) 2018-04-06 2022-05-18 The Regents of The University of California METHODS OF TREATMENT OF EGFRVIII-EXPRESSING GLIOBLASTOMA
CN112368011A (zh) 2018-04-11 2021-02-12 俄亥俄州创新基金会 缓释微粒用于眼用药物递送的方法和组合物
MX2021000644A (es) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.
WO2020148612A1 (en) 2019-01-14 2020-07-23 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
CA3129883A1 (en) 2019-02-14 2020-08-20 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
BR112021019701A2 (pt) 2019-04-02 2021-12-14 Kenjockety Biotechnology Inc Anticorpos multiespecíficos para antígeno de câncer de bomba de efluxo e composições, reagentes, kits e métodos relacionados aos mesmos
CA3163805A1 (en) 2019-12-12 2021-06-17 Ignite Immunotherapy, Inc. Variant oncolytic vaccinia virus and methods of use thereof
BR112022013870A2 (pt) 2020-01-29 2022-09-13 Kenjockety Biotechnology Inc Anticorpos anti-mdr1 e usos dos mesmos
WO2021247426A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
EP4161564A1 (en) 2020-06-04 2023-04-12 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
US20220033784A1 (en) 2020-07-14 2022-02-03 Pfizer Inc. Recombinant vaccinia virus
JP7747741B2 (ja) 2020-09-02 2025-10-01 ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 抗ａｂｃｃ１抗体及びその使用
EP4244257A1 (en) 2020-11-13 2023-09-20 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
MX2023005979A (es) 2020-11-20 2023-08-11 Scherer Technologies Llc R P Enlazadores de escisión doble de glicósido para conjugados de anticuerpo y fármaco.
KR20240116829A (ko) 2021-12-13 2024-07-30 윌리엄 로버트 아라툰 리빙 트러스트 데이티드 어거스트 29, 2016 항-abcb1 항체
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032576A (enExample) * 1976-01-08 1977-06-28
DE2655004C3 (de) * 1976-12-02 1980-06-19 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von bicyclischen Laktonen
DE3574470D1 (en) * 1985-09-18 1990-01-04 Upjohn Co Stereoselective reduktion.
JPS62153259A (ja) * 1985-12-26 1987-07-08 Sagami Chem Res Center （２−クロロ−３−オキソ−１−アルケニル）−ビシクロ〔３．３．０〕オクテン誘導体及びその製法
DE3620442A1 (de) * 1986-06-18 1987-12-23 Merck Patent Gmbh Ketolactone
EP0394263B1 (en) * 1987-09-04 1994-03-16 The Upjohn Company Process for production of prostaglandin intermediates

Also Published As

Publication number Publication date
CA2064481A1 (en) 1992-10-05
DE69213067D1 (de) 1996-10-02
CA2064481C (en) 1996-12-24
TW197439B (enExample) 1993-01-01
US5229529A (en) 1993-07-20
KR970003125B1 (ko) 1997-03-14
GR3020903T3 (en) 1996-11-30
KR920019771A (ko) 1992-11-20
ATE141921T1 (de) 1996-09-15
DE69213067T2 (de) 1997-01-16
EP0507625A1 (en) 1992-10-07
JPH089608B2 (ja) 1996-01-31
DK0507625T3 (da) 1996-09-16
JPH0592965A (ja) 1993-04-16
EP0507625B1 (en) 1996-08-28

Similar Documents

Publication Publication Date Title
TW197439B (enExample)
ATE194601T1 (de) Verfahren zur herstellung von pyrimidinverbindungen
MX17846A (es) Proceso para la preparacion de nuevos derivados de 9h purina.
IT8219278A0 (it) Procedimento per la produzione di una grafite fluorurata comprendente principalmente polidicarbomonofluoruro rappresentato dalla formula (c2f)n.
IT7819980A0 (it) Procedimento per la produzione di oggetti di carbonio o grafite con elevata solidita'.
ES543153A0 (es) Metodo de preparar derivados de b-carbolin-3-oxadiazolilo
ES2060354T3 (es) Procedimiento para la obtencion de esclareoluro.
NO922321D0 (no) Bis(fluormetyl)eter, fremgangsmaate for fremstilling, samtfremgangsmaate for fremstilling av difluormetan av bis(fluormetyl)eter
ES2057289T3 (es) Procedimiento para la obtencion de octadienoles.
ATE38986T1 (de) Verfahren zur herstellung 1,6-disubstituierter 2- aminobenzimidazole.
ES2177877T3 (es) Procedimiento para la fabricacion de 1,4-bis(aminometil)ciclohexano.
MA18596A1 (fr) Derives halogenes de 1-azolyl-1 fluorophenoxybutane, leur production et leur application comme fongicides
ES476420A1 (es) Procedimiento para la obtencion de un o-ftalaldehido, en ca-so dado sustituido.
ES2111234T3 (es) Procedimiento para la obtencion de 4,5-difluorbenzaldehidos.
ES2077781T3 (es) Procedimiento para la fabricacion de difosfanos solubles al agua.
DK0643051T3 (da) Fremgangsmåde til fremstilling af alfa,beta-umættede ketoner
ES536973A0 (es) Metodo de preparar dimetiloctenonas
ES2017477B3 (es) Procedimiento para la preparacion de bisfenoles bromados.
IT1239163B (it) Procedimento per la produzione di feltri per cappello.
BG43006A3 (en) Method for preparing condensed as- triazines
IL101052A (en) Process for producing glyceraldehyde- 3-pentanide
MX9205610A (es) Procedimiento para la preparacion de: acido (+ -)-2(6-metoxi-2-naftil)-propionico.
GB2097792B (en) 1,3-dihydro-2h-imidazol-2-ones
BG43005A3 (bg) Метод за получаване на кондензирани аs-триазини
ES535991A0 (es) Un procedimiento para preparar un 10-ftalil-1, 5-diprotegido-1, 5, 10-triazadecano

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 507625

Country of ref document: ES